Centuple Global

Which are the latest news on Centuple Global?

Why is Centuple Global Ltd falling/rising?

As of 05-Sep, Centuple Global Ltd's stock price is declining, currently at Rs 35.72, reflecting a 4.97% drop and underperformance against the sector. The stock is trading below all key moving averages, indicating a bearish outlook, compounded by decreased investor participation.

As of 05-Sep, Centuple Global Ltd's stock price is falling, currently at Rs 35.72, which represents a decrease of Rs 1.87 or 4.97%. This decline is evident in the stock's performance today, where it underperformed the sector by 4.52%. The stock has also experienced a trend reversal, having fallen after two consecutive days of gains. <BR><BR>Additionally, the stock touched an intraday low of Rs 35.72, indicating significant selling pressure. The weighted average price suggests that more volume was traded close to this low price, further confirming the downward trend. Centuple Global is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which typically signals a bearish outlook.<BR><BR>Investor participation has also decreased, with delivery volume on September 3 dropping by 95.73% compared to the 5-day average. This lack of interest from investors contributes to the stock's decline. Overall, the combination of negative performance metrics and reduced investor activity is driving the stock price down.

Who are in the management team of Centuple Global?

The management team of Centuple Global includes Abha Kapoor (CFO), Sunil Khandelwal (Managing Director), and independent directors Sneha Thakur, Gopal Sahu, and Harish Surve, along with Ritu Chhatani as Company Secretary. They oversee the company's operations and strategic direction.

The management team of Centuple Global includes the following individuals:<BR><BR>1. **Abha Kapoor** - Director (Finance) & CFO<BR>2. **Sneha Thakur** - Independent Director<BR>3. **Sunil Khandelwal** - Managing Director<BR>4. **Gopal Sahu** - Independent Director<BR>5. **Ritu Chhatani** - Company Secretary & Compliance Officer<BR>6. **Harish Surve** - Independent Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction. If you have any more questions about Centuple Global or its management, feel free to ask!

What does Centuple Global do?

Centuple Global Ltd is a micro-cap company in the Pharmaceuticals & Biotechnology industry, primarily focused on trading and consulting services. Established in 1991, it reported a net profit of 0 Cr for June 2026 and has a market cap of INR 20 Cr.

Overview: <BR>Centuple Global Ltd operates in the Pharmaceuticals & Biotechnology industry as a micro-cap company, primarily engaged in trading and providing various consulting services.<BR><BR>History: <BR>Centuple Global Ltd was established in 1991 and was formerly known as Rubra Medicaments Ltd. The company changed its name to Checkpoint Trends Limited in April 2022. The most recent quarterly results reported net profit for June 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 20 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 13.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.07 <BR>Return on Equity: 76.14% <BR>Price-to-Book: 10.96 <BR><BR>Contact Details: <BR>Address: 604 6th Floor Meghdoot, Mogul Lines Staff CHSL JVPD Sc Mumbai Maharashtra : 400049 <BR>Tel: 91-9167469649 <BR>Email: rubraltd@gmail.com <BR>Website: http://www.rubramed.com

Who are the peers of the Centuple Global?

Centuple Global's peers include Guj. Terce Labs, Cian Healthcare, Welcure Drugs, Venmax Drugs, Ishita Drugs, Shree Ganesh Bio, Colinz Labs, Bacil Pharma, and Zenith Health. Centuple Global exhibits excellent management risk and good growth, while its peers generally show below average to average management risk and growth, with Cian Healthcare having the highest 1-year return at 252.28% and Welcure Drugs the lowest at -72.73%.

Peers: The peers of Centuple Global are Guj. Terce Labs., Cian Healthcare, Welcure Drugs, Venmax Drugs, Ishita Drugs, Shree Ganesh Bio, Colinz Labs, Bacil Pharma, and Zenith Health.<BR><BR>Quality Snapshot: Excellent management risk is observed at Centuple Global, while Below Average management risk is found at Guj. Terce Labs., Cian Healthcare, Venmax Drugs, Ishita Drugs, Shree Ganesh Bio, Colinz Labs, and Zenith Health, and the rest. Average management risk is noted at Welcure Drugs. In terms of growth, Centuple Global shows Good growth, while Average growth is seen at Guj. Terce Labs. and Venmax Drugs, and Below Average growth is found at Cian Healthcare, Welcure Drugs, Ishita Drugs, Shree Ganesh Bio, Colinz Labs, and Zenith Health, and the rest. Capital Structure is Good at Centuple Global, Welcure Drugs, Ishita Drugs, Shree Ganesh Bio, Colinz Labs, and Zenith Health, while Below Average is observed at Guj. Terce Labs., Cian Healthcare, Venmax Drugs, and the rest.<BR><BR>Return Snapshot: Cian Healthcare has the highest 1-year return at 252.28%, while Welcure Drugs has the lowest at -72.73%. Centuple Global's 1-year return of 22.32% is significantly higher than that of Welcure Drugs. Additionally, peers such as Venmax Drugs, Ishita Drugs, Shree Ganesh Bio, and Zenith Health have negative six-month returns.

How big is Centuple Global?

As of 31st August, Centuple Global Ltd has a market capitalization of 20.00 Cr, with net sales of 562.09 Cr and a net profit of 1.23 Cr reported in the latest four quarters. Shareholder's funds are 0.56 Cr and total assets are valued at 0.65 Cr as of March 2025.

As of 31st August, Centuple Global Ltd has a market capitalization of 20.00 Cr, which categorizes it as a Micro Cap company.<BR><BR>In the latest four quarters, Centuple Global reported net sales of 562.09 Cr and a net profit of 1.23 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with shareholder's funds amounting to 0.56 Cr and total assets valued at 0.65 Cr.

Should I buy, sell or hold Checkpoint Trends Ltd?

When is the next results date for Checkpoint Trends Ltd?

The next results date for Checkpoint Trends Ltd is not specified. Centuple Global will announce its results on 13 August 2026.

The next results date for Checkpoint Trends Ltd is not specified in the information available. However, Centuple Global will declare its results on 13 August 2026. If you need further details about Checkpoint Trends Ltd specifically, please let me know.

Are Checkpoint Trends Ltd latest results good or bad?

Checkpoint Trends Ltd's latest results show impressive revenue growth of 111,664% year-over-year, reaching ₹279.41 crores, but the company reported a net loss of ₹0.48 crores and negative operating margins, raising concerns about its profitability and financial sustainability. Investors should be cautious and monitor the company's ability to improve margins in future quarters.

The latest results for Checkpoint Trends Ltd (formerly Centuple Global) present a mixed picture. On one hand, the company has achieved remarkable revenue growth, with net sales soaring by 111,664% year-over-year, reaching ₹279.41 crores in Q4 FY26. This significant increase indicates a successful scaling of operations and a dramatic transformation from previous years.<BR><BR>However, the financial performance is marred by a net loss of ₹0.48 crores for the quarter, a stark contrast to the profit of ₹0.06 crores reported in the same quarter last year. This represents a concerning decline in profitability, especially given that the operating margin has turned negative at -0.14%, down from 36.0% the previous year. The company's inability to convert its substantial revenue growth into profits raises questions about the sustainability of its business model.<BR><BR>Additionally, the return on equity (ROE) is notably high at 104.42%, but this figure must be interpreted cautiously due to the minimal equity base and the recent losses. The overall financial health appears precarious, with operational challenges evident in the negative operating profit before depreciation, interest, and tax (PBDIT) of ₹-0.38 crores.<BR><BR>In summary, while the explosive revenue growth is a positive sign, the company's current financial results reflect significant challenges in achieving profitability, making the overall outlook quite concerning. Investors should be cautious and closely monitor the company's ability to recover margins in the upcoming quarters.

Is Checkpoint Trend overvalued or undervalued?

As of November 13, 2025, Checkpoint Trend is considered undervalued with a favorable valuation grade shift, featuring a PE ratio of 30.19 and a year-to-date return of 512.18%, significantly outperforming its peers and the Sensex.

As of 13 November 2025, Checkpoint Trend's valuation grade has moved from very expensive to attractive, indicating a significant shift in its market perception. The company is currently assessed as undervalued, particularly in light of its impressive financial metrics. Key ratios include a PE ratio of 30.19, an EV to EBITDA ratio of 22.62, and a PEG ratio of 0.04, which suggests strong growth potential relative to its price.<BR><BR>In comparison to its peers, Checkpoint Trend's valuation appears favorable. For instance, Sun Pharma has a PE ratio of 36.15 and an EV to EBITDA of 23.85, while Cipla, which is also rated attractive, has a PE of 22.65. Notably, Checkpoint Trend's return performance has significantly outpaced the Sensex, with a year-to-date return of 512.18% compared to the Sensex's 8.11%, reinforcing the notion that the stock is undervalued relative to its growth trajectory.

How has been the historical performance of Checkpoint Trend?

Checkpoint Trend's historical performance shows a decline in net sales from 2.01 Cr in Mar'22 to 0.50 Cr in Mar'25, with total operating income and expenditures also decreasing. However, operating profit improved from a loss in Mar'23 to a profit in Mar'25, while total assets and liabilities decreased, indicating a stagnant cash position.

Answer:<BR>The historical performance of Checkpoint Trend shows a fluctuating trend in net sales and profitability over the years.<BR><BR>Breakdown:<BR>Checkpoint Trend's net sales have seen a decline from 2.01 Cr in Mar'22 to 0.50 Cr in Mar'25, with a notable drop from 1.16 Cr in Mar'23. The total operating income followed a similar trend, decreasing from 2.01 Cr in Mar'22 to 0.50 Cr in Mar'25. The company's total expenditure, excluding depreciation, also decreased from 2.03 Cr in Mar'22 to 0.44 Cr in Mar'25. Operating profit (PBDIT) showed a slight improvement, moving from a loss of 0.08 Cr in Mar'23 to a profit of 0.06 Cr in Mar'25. Profit before tax improved from a loss of 0.08 Cr in Mar'23 to a profit of 0.05 Cr in Mar'25, while profit after tax remained stable at 0.03 Cr for both Mar'24 and Mar'25. The company's total assets decreased from 0.93 Cr in Mar'24 to 0.65 Cr in Mar'25, and total liabilities also declined from 0.93 Cr to 0.65 Cr in the same period. Cash flow figures indicate no cash inflow or outflow across the years, reflecting a stagnant cash position.

Who are the top shareholders of the Checkpoint Trend?

The top shareholders of Checkpoint Trend are individual investors with 71.77% of shares, followed by Religare Finvest Ltd at 5.89%, and two foreign institutional investors holding a combined 10.85%. There are no pledged promoter holdings or mutual funds in the shareholding structure.

The top shareholders of Checkpoint Trend include individual investors, who hold a significant 71.77% of the shares. Additionally, Religare Finvest Ltd is the highest public shareholder with a stake of 5.89%. The company also has two foreign institutional investors (FIIs) holding a combined 10.85%. There are no pledged promoter holdings or mutual funds involved in the shareholding structure.

What is the technical trend for Checkpoint Trend?

As of May 29, 2025, Checkpoint Trend shows a mildly bullish outlook, supported by daily moving averages and monthly KST, despite some short-term bearish signals from weekly MACD and RSI.

As of 29 May 2025, the technical trend for Checkpoint Trend has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by the daily moving averages indicating mild bullishness and the monthly KST remaining bullish. However, the weekly MACD and RSI are showing mildly bearish and bearish signals respectively, which temper the overall bullish outlook. The Bollinger Bands are also indicating mild bullishness on both weekly and monthly time frames. Overall, while there are some bearish signals in the short term, the longer-term indicators suggest a cautiously optimistic view.

Has Checkpoint Trend declared dividend?

No Dividend History Available